Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Helmschrott

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Cardiovascular Development and Disease|October 26, 2022
Frequency, Risk Factors, and Clinical Outcomes of Late-Onset Atrial Flutter in Patients after Heart TransplantationAnn-Kathrin Rahm, Susanne Reinhardt, Matthias Helmschrott, et al.
Life (Basel, Switzerland)|December 24, 2021
Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart TransplantationKarsten M Heil, Matthias Helmschrott, Fabrice F Darche, et al.
ESC Heart Failure|August 28, 2021
Atrial fibrillation before heart transplantation is a risk factor for post-transplant atrial fibrillation and mortalityFabrice F Darche, Matthias Helmschrott, Ann-Kathrin Rahm, et al.
Frontiers in Cardiovascular Medicine|June 27, 2022
Pre-transplant Type 2 Diabetes Mellitus Is Associated With Higher Graft Failure and Increased 5-Year Mortality After Heart TransplantationRasmus Rivinius, Carolin Gralla, Matthias Helmschrott, et al.
Drug Design, Development and Therapy|September 24, 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimenMatthias Helmschrott, Jan Beckendorf, Ceylan Akyol, et al.
Drug Design, Development and Therapy|March 12, 2015
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantationMatthias Helmschrott, Rasmus Rivinius, Arjang Ruhparwar, et al.
Drug Design, Development and Therapy|May 1, 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantationIbrahim Gueler, Susanne Mueller, Matthias Helmschrott, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 9, 2017
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern eraArnt V Kristen, Michael M Kreusser, Patrick Blum, et al.
Drug Design, Development and Therapy|January 2, 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapyRasmus Rivinius, Matthias Helmschrott, Arjang Ruhparwar, et al.
Drug Design, Development and Therapy|March 4, 2016
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantationRasmus Rivinius, Matthias Helmschrott, Arjang Ruhparwar, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Cardiovascular Development and Disease|October 26, 2022
Frequency, Risk Factors, and Clinical Outcomes of Late-Onset Atrial Flutter in Patients after Heart TransplantationAnn-Kathrin Rahm, Susanne Reinhardt, Matthias Helmschrott, et al.
Life (Basel, Switzerland)|December 24, 2021
Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart TransplantationKarsten M Heil, Matthias Helmschrott, Fabrice F Darche, et al.
ESC Heart Failure|August 28, 2021
Atrial fibrillation before heart transplantation is a risk factor for post-transplant atrial fibrillation and mortalityFabrice F Darche, Matthias Helmschrott, Ann-Kathrin Rahm, et al.
Frontiers in Cardiovascular Medicine|June 27, 2022
Pre-transplant Type 2 Diabetes Mellitus Is Associated With Higher Graft Failure and Increased 5-Year Mortality After Heart TransplantationRasmus Rivinius, Carolin Gralla, Matthias Helmschrott, et al.
Drug Design, Development and Therapy|September 24, 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimenMatthias Helmschrott, Jan Beckendorf, Ceylan Akyol, et al.
Drug Design, Development and Therapy|March 12, 2015
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantationMatthias Helmschrott, Rasmus Rivinius, Arjang Ruhparwar, et al.
Drug Design, Development and Therapy|May 1, 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantationIbrahim Gueler, Susanne Mueller, Matthias Helmschrott, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 9, 2017
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern eraArnt V Kristen, Michael M Kreusser, Patrick Blum, et al.
Drug Design, Development and Therapy|January 2, 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapyRasmus Rivinius, Matthias Helmschrott, Arjang Ruhparwar, et al.
Drug Design, Development and Therapy|March 4, 2016
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantationRasmus Rivinius, Matthias Helmschrott, Arjang Ruhparwar, et al.
Pageof 4